1. Home
  2. AEYE vs VRCA Comparison

AEYE vs VRCA Comparison

Compare AEYE & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AudioEye Inc.

AEYE

AudioEye Inc.

SELL

Current Price

$6.66

Market Cap

86.2M

Sector

Technology

ML Signal

SELL

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$3.60

Market Cap

88.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEYE
VRCA
Founded
2005
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
86.2M
88.0M
IPO Year
2011
2018

Fundamental Metrics

Financial Performance
Metric
AEYE
VRCA
Price
$6.66
$3.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
★ $17.33
$13.83
AVG Volume (30 Days)
★ 63.8K
45.3K
Earning Date
11-03-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 30.56
N/A
EPS
★ N/A
N/A
Revenue
★ $40,311,000.00
$35,577,000.00
Revenue This Year
$8.25
N/A
Revenue Next Year
$10.24
$58.01
P/E Ratio
★ N/A
N/A
Revenue Growth
14.52
★ 370.22
52 Week Low
$5.31
$3.28
52 Week High
$16.39
$9.82

Technical Indicators

Market Signals
Indicator
AEYE
VRCA
Relative Strength Index (RSI) 43.11 31.28
Support Level $6.61 N/A
Resistance Level $7.32 $5.94
Average True Range (ATR) 0.31 0.36
MACD -0.01 -0.05
Stochastic Oscillator 9.76 3.25

Price Performance

Historical Comparison
AEYE
VRCA

About AEYE AudioEye Inc.

AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Share on Social Networks: